Exclusive License

An exclusive license gives one licensee sole rights within a defined scope: DEFINITION: in an exclusive license, the licensor grants a right to practice the patent AND covenants not to grant the same rights to any other party; WHAT THE LICENSOR PROMISES: no other licenses to third parties within the same scope (field, territory, time period); the licensor warrants peaceful enjoyment of the licensed scope against third parties; WHAT THE LICENSOR MAY RETAIN: the right to practice the patent itself (unless the license specifically prohibits this — creating a 'sole license' vs. a fully exclusive license); the right to grant licenses in different fields/territories; SOLE LICENSE vs. FULLY EXCLUSIVE LICENSE: sole license: the licensor and licensee BOTH can practice the patent in the licensed scope, but no third parties can get the same license; fully exclusive license: ONLY the licensee can practice the patent in the licensed scope; the licensor cannot practice either; DISTINGUISHING BY CONTEXT: in a startup company acquiring a university patent, a fully exclusive license (licensor cannot practice) is common; in a large-company-to-large-company deal, a sole license (both parties can practice) may be the outcome; PARTIAL EXCLUSIVITY: exclusive for some scope, non-exclusive for others; exclusive for 5 years, then non-exclusive; exclusive in some territories, non-exclusive worldwide; GRANT-BACK PROVISIONS: exclusive licenses often require the licensee to grant back a license (exclusive or non-exclusive) on improvements to the licensed technology; highly negotiated — licensee resists broad grant-back as it reduces the incentive to improve; licensor wants broad grant-back to maintain control of the technology direction.

University technology transfer relies heavily on exclusive licensing to commercialize academic research: WHY UNIVERSITIES LICENSE EXCLUSIVELY: universities do not commercialize technology themselves; they license to startups or established companies who will develop and bring the technology to market; an exclusive license gives the licensee the security to invest in development (clinical trials, product development, manufacturing scale-up); without exclusivity, a licensee's competitor could get the same rights and undercut the investment; BAYH-DOLE ACT FRAMEWORK: universities that receive federal funding must use Bayh-Dole Act procedures for licensing inventions developed with federal support; march-in rights: the government can require the university to license to a third party if the patent owner fails to commercialize; national manufacturing preference for US-manufactured goods; TYPICAL UNIVERSITY EXCLUSIVE LICENSE TERMS: upfront license fee: $10K-$100K+ depending on stage of development; annual maintenance fees: $10K-$50K+ (increases over time); milestone payments: $50K-$500K+ at IND filing, Phase II, FDA approval, first commercial sale; running royalties: 3-8% of net sales; minimum annual royalties: $50K-$500K+ after first commercial sale; diligence obligations: specific development milestones the licensee must meet; SUBLICENSING IN UNIVERSITY LICENSES: universities commonly allow sublicensing; the university receives a share of sublicense income (25-50% is common); some universities require approval of sublicenses to ensure quality; PATENT PROSECUTION COSTS: in university licenses, the university often controls prosecution; licensee reimburses prosecution costs; licensee may get input on prosecution strategy; PROSECUTION RIGHTS NEGOTIATION: sophisticated licensees want control over or input into prosecution decisions that affect their licensed claims.

Exclusive licensors face a risk: the exclusive licensee may block others from using the technology without actually developing it: DILIGENCE OBLIGATIONS: exclusive licenses almost always include affirmative obligations on the licensee to commercialize the technology; typical diligence provisions: file IND by date X; complete Phase II by date Y; file NDA by date Z; achieve first commercial sale by date W; spend minimum dollar amount on development annually; FAILURE TO MEET DILIGENCE: if licensee fails to meet diligence milestones, licensor may: terminate the license; convert to non-exclusive; grant additional licenses to third parties; the license should specify exactly what constitutes failure and what cure period applies; MINIMUM ROYALTY OBLIGATIONS: once the product is commercialized, the licensor wants guaranteed income; minimum annual royalties ensure the licensee actively markets the product; typical: $100K-$500K+ per year after first commercial sale; if minimums not met, licensor can: terminate the license; convert to non-exclusive; accept the shortfall; best practice: licensor should negotiate automatic non-exclusive conversion (not termination) for minimum royalty shortfall — termination triggers dispute; MARCH-IN RIGHTS (BAYH-DOLE CONTEXT): for federally funded inventions, the government has march-in rights if the licensee: fails to achieve practical application of the invention within a reasonable time; fails to satisfy health or safety needs; fails to meet requirements of public use; ANTI-SHELVING PROVISIONS: prevent the licensee from acquiring the license solely to block competition without developing the technology; include: minimum development spending; minimum commercial sales targets; publication of progress reports to licensor; COMMERCIALIZATION PLANS: require the licensee to provide an initial commercialization plan and update it annually.

Exclusive patent licenses involve multiple financial provisions that must be carefully negotiated: UPFRONT LICENSE FEE: paid upon execution of the license agreement; represents immediate value to the licensor; not refundable if the licensee fails; typically $10K-$5M+ depending on stage of development and strategic value; ANNUAL MAINTENANCE/EXCLUSIVITY FEE: paid each year the license remains exclusive; compensates the licensor for the opportunity cost of not licensing to others; increases over time as the market value becomes clearer; MILESTONE PAYMENTS: payable upon achieving specific events; common milestones in pharma: IND filing ($100K-$500K); Phase I completion ($250K-$1M); Phase II initiation ($500K-$2M); Phase III initiation ($1M-$5M); NDA/BLA filing ($2M-$10M); regulatory approval ($5M-$50M); first commercial sale ($10M-$100M); RUNNING ROYALTIES: percentage of net sales for the duration of the patent term; exclusive licensee typically pays higher royalty than a non-exclusive licensee (2-15%+ depending on industry); ROYALTY STACKING PROVISION: licensee may negotiate a royalty reduction if it must pay royalties to additional third parties for blocking patents; total stacked royalties capped at X%; MOST-FAVORED-LICENSEE (MFL): if licensor later grants a license to another party on more favorable terms, the original licensee gets the benefit of those terms; protects licensee against licensor renegotiating better deals for others; relevant in field-of-use contexts where multiple licensees in different fields may be negotiated sequentially; SUBLICENSE INCOME SHARING: if the licensee sublicenses, the licensor receives a share; typically 25-50% of running royalties paid by sublicensees; for non-royalty sublicense income (lump sum, milestone), the percentage may be higher; REIMBURSEMENT OF PATENT PROSECUTION COSTS: ongoing prosecution expenses passed through to licensee.

Termination of exclusive licenses must be carefully managed to protect both parties: GROUNDS FOR TERMINATION: FOR CAUSE BY LICENSOR: failure to pay royalties (after cure period); failure to meet diligence milestones (after cure period); insolvency or bankruptcy of licensee; breach of representations and warranties; challenge to patent validity (if anti-challenge clause is enforceable); FOR CAUSE BY LICENSEE: licensor's material breach; patent ceases to exist (expired, held invalid, or abandoned); TERMINATION FOR CONVENIENCE: either party may terminate for convenience with notice period (typically 30-90 days); licensee may negotiate a minimum license term before termination for convenience is allowed; EFFECTS OF TERMINATION: licensor's perspective: the patent rights revert to the licensor; licensor can grant new licenses; any ongoing royalties from sublicensees may or may not survive (depends on contract); licensee's perspective: must stop practicing the patent; loses the investment in commercialization unless sublicenses survive; existing sublicensees may face uncertainty; ANTI-CHALLENGE CLAUSES: some exclusive licenses prohibit the licensee from challenging the validity of the licensed patent; enforceability varies by jurisdiction; US: not per se unenforceable but must be carefully drafted; EU: may violate competition law in some circumstances; MedImmune v. Genentech (S.Ct. 2007): a licensee in good standing CAN bring a declaratory judgment action for invalidity despite anti-challenge clause — licensee doesn't have to breach the license first to bring an invalidity challenge; BANKRUPTCY CONSIDERATIONS: § 365(n) of the Bankruptcy Code: if the licensor (debtor) rejects the license in bankruptcy, the licensee can: elect to retain its rights under the license (paying royalties); or accept the rejection and treat it as a breach (recovering damages); this protects licensees from losing rights when a licensor files for bankruptcy.